SLANG Worldwide Past Earnings Performance
Past criteria checks 0/6
SLANG Worldwide has been growing earnings at an average annual rate of 19.3%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 21.2% per year.
Key information
19.3%
Earnings growth rate
42.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 21.2% |
| Return on equity | n/a |
| Net Margin | -54.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?
Dec 26
Is SLANG Worldwide (CSE:SLNG) A Risky Investment?
Sep 09Is SLANG Worldwide (CSE:SLNG) A Risky Investment?
May 26Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?
Mar 28Is SLANG Worldwide (CSE:SLNG) Using Too Much Debt?
Dec 11The SLANG Worldwide (CSE:SLNG) Share Price Is Up 92% And Shareholders Are Holding On
Mar 02Revenue & Expenses BreakdownBeta
How SLANG Worldwide makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 35 | -19 | 22 | 0 |
| 30 Sep 23 | 40 | -26 | 23 | 0 |
| 30 Jun 23 | 39 | -27 | 24 | 0 |
| 31 Mar 23 | 40 | -28 | 25 | 0 |
| 31 Dec 22 | 38 | -29 | 26 | 0 |
| 30 Sep 22 | 35 | -47 | 28 | 0 |
| 30 Jun 22 | 36 | -48 | 30 | 0 |
| 31 Mar 22 | 37 | -48 | 31 | 0 |
| 31 Dec 21 | 37 | -51 | 33 | 0 |
| 30 Sep 21 | 36 | -52 | 29 | 0 |
| 30 Jun 21 | 34 | -52 | 25 | 0 |
| 31 Mar 21 | 26 | -45 | 27 | 0 |
| 31 Dec 20 | 22 | -14 | 27 | 0 |
| 30 Sep 20 | 21 | -187 | 49 | 0 |
| 30 Jun 20 | 23 | -178 | 53 | 0 |
| 31 Mar 20 | 27 | -162 | 52 | 0 |
| 31 Dec 19 | 26 | -200 | 51 | 0 |
| 30 Sep 19 | 22 | 9 | 28 | 0 |
| 30 Jun 19 | 15 | -10 | 31 | 0 |
| 31 Mar 19 | 8 | -42 | 26 | 0 |
| 31 Dec 18 | 5 | -28 | 20 | 0 |
| 30 Sep 18 | 3 | -31 | 15 | 0 |
| 31 Dec 17 | 0 | -1 | 0 | 0 |
Quality Earnings: SLNG is currently unprofitable.
Growing Profit Margin: SLNG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SLNG is unprofitable, but has reduced losses over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare SLNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLNG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: SLNG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.